Alps Group Inc Launches Pharmaco-Interaction (PCI) Unit via MyGenome, Debuting with CYP450 Drug Interaction Testing

The new unit adds a commercial testing service to MyGenome’s laboratory portfolio for manufacturers and research institutions.

Rhea-AI Summary

Alps Group (Nasdaq: ALPS) launched a Pharmaco-Interaction laboratory unit within MyGenome, debuting drug interaction testing as its first commercial service offering.

The Kuala Lumpur unit will begin with CYP450 inhibitory IC50 testing, which measures inhibition of enzymes involved in drug metabolism. The service will be available to herbal and supplement manufacturers, pharmaceutical companies, and research institutions. FDA and EMA guidelines recommend CYP inhibition evaluation for clinical and botanical drugs. Alps describes the launch as a step toward its goal of becoming a regional life sciences reference platform.

Positive

• Minor pointMyGenome’s new PCI unit launches with CYP450 drug interaction testing as its first commercial service offering.

Negative

• None.

Key Figures

Enzyme isoforms tested: 7 isoforms Marketed clinical drugs metabolized: Approximately 90%

Enzyme isoforms tested

7 isoforms

Initial CYP450 inhibitory IC50 testing service

Marketed clinical drugs metabolized

Approximately 90%

Collectively metabolized by the seven enzyme isoforms

Key Terms

cyp450, ic50, lc-ms/ms, triple quadrupole

4 terms

cyp450 technical

"CYP450 inhibitory IC50 testing debuting as its first commercial service offering."

A family of enzymes (cytochrome P450) found mainly in the liver and other tissues that chemically modify drugs, hormones, toxins and other organic compounds to aid their elimination or activation. Different CYP450 isoforms each act on particular substances; variation in which isoforms metabolize a drug determines how quickly the drug is cleared, whether it is converted into an active or toxic form, and which drug–drug interactions can occur when one medicine alters the activity of an enzyme that handles another. Genetic differences, certain foods and other medicines can increase or decrease CYP450 enzyme activity, changing metabolism rates for affected drugs.

ic50 technical

"CYP450 inhibitory IC50 testing debuting as its first commercial service offering."

IC50 is the concentration of a drug or compound needed to reduce a specific biological activity by half, commonly used to compare how potent experimental treatments are in laboratory tests. For investors, a lower IC50 often signals a stronger candidate that may require smaller doses, influence development costs, safety margins and competitive positioning, so it offers an early measure of technical promise though it does not guarantee clinical or commercial success.

lc-ms/ms technical

"LC-MS/MS Triple Quadrupole used for CYP450 inhibitory IC50 testing"

LC‑MS/MS is a laboratory technique that first separates a mixture of chemicals in a liquid, then identifies and measures each component with very high sensitivity—think of sorting mixed mail and then scanning barcodes to know exactly what’s inside. It matters to investors because it produces precise, reliable data used in drug development, safety testing, diagnostics and product quality control, and those results influence regulatory approvals, market access and commercial claims that can affect a company’s value.

triple quadrupole technical

"LC-MS/MS Triple Quadrupole used for CYP450 inhibitory IC50 testing"

A triple quadrupole is a type of mass spectrometer made of three sequential quadrupole mass filters used for tandem mass spectrometry (MS/MS). The first quadrupole (Q1) selects ions of a chosen mass-to-charge ratio, the second (Q2) serves as a collision cell where selected ions are fragmented, and the third (Q3) analyzes the fragment (product) ions; this arrangement enables highly sensitive and selective detection and quantification of target molecules. It provides unit-mass resolution and excellent quantitative performance but is not a high-resolution/accurate-mass instrument.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PCI Positions MyGenome as Southeast Asia's Reference Laboratory for Drug Interaction Safety Science

KUALA LUMPUR, Malaysia, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced the launch of its Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing debuting as its first commercial service offering.

The MyGenome laboratory facility in Kuala Lumpur, Malaysia, home to the newly launched Pharmaco-Interaction (PCI) unit.

PCI will start with cytochrome P450 (CYP450) inhibitory IC50 testing across seven major enzyme isoforms (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2B6, and CYP2E1), collectively responsible for metabolizing approximately 90% of marketed clinical drugs, supporting safe use, regulatory compliance, and consumer confidence. FDA and EMA guidelines recommend CYP inhibition evaluation for clinical and botanical drugs. PCI will make this service available to herbal and supplement manufacturers, pharmaceutical companies, and research institutions.

“Every service we launch is a building block toward becoming Southeast Asia’s integrated life sciences reference platform,” said Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc. “The region has a significant and growing herbal and botanical products industry, yet access to accredited CYP inhibition testing has remained limited. PCI addresses that gap converting our scientific infrastructure into a revenue-generating capability that meets the regulatory standards already demanded by the market.”

“The assumption that all natural products are inherently safe, especially in consumption with prescription drugs, is one of the most persistent misconceptions in healthcare,” said Professor Nik Soriani, PCI Scientific Lead at MyGenome. “CYP450 inhibition testing is already recommended by the FDA and EMA for clinical and botanical products. PCI intends to make that standard accessible to manufacturers and researchers across Southeast Asia. We are building the reference laboratory Southeast Asia has been missing.”

LC-MS/MS Triple Quadrupole used for CYP450 inhibitory IC50 testing across seven major enzyme isoforms at Alps Group Inc’s MyGenome subsidiary.

PCI joins a growing suite of high-value B2B services within Alps’ laboratory portfolio, as the Company expands its capabilities across precision oncology, genomics, and translational research, with the goal of establishing Malaysia as a regional hub for ethical life science services.

About Alps Group Inc
Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.

Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

Investor Relations Contact
Alps Group Inc
Investor Relations
Phone: +60 3-2163 1113
Email: investorrelations@alpsmedical.com 

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/66efa1e1-8981-46a8-a974-28de896bd6f0

https://www.globenewswire.com/NewsRoom/AttachmentNg/6cbc1f80-900a-4ccd-acbd-1b63ea07f790

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What service is Alps Group launching through MyGenome’s PCI unit?

MyGenome’s new Pharmaco-Interaction unit is debuting CYP450 inhibitory IC50 testing as its first commercial service offering. The testing measures inhibition of enzymes involved in drug metabolism and will be available to herbal and supplement manufacturers, pharmaceutical companies, and research institutions.